Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Status:	Completed
Conditions:	Infectious Disease, Hepatitis
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	4/5/2019
Start Date:	April 25, 2017
End Date:	March 19, 2018

An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

The primary objectives of this study are to determine the efficacy, safety, and tolerability
of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination
(FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection with or
without cirrhosis, who did not achieve sustained viral response (SVR) after receiving prior
treatment in a Gilead-sponsored HCV treatment study of direct-acting antiviral
(DAA)-containing regimens.

Key Inclusion Criteria:

- Chronically HCV-infected males and non-pregnant/non-lactating females aged 18 years or
older who did not achieve sustained virologic response (SVR) in a prior
Gilead-sponsored HCV treatment study

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

We found this trial at

sites

Emory Hospital Midtown Infectious Disease Clinic

550 Peachtree Street Northeast
Atlanta, Georgia 30308

from

Atlanta, GA